Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) Director Warren Whitehead sold 5,000 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of C$9.69, for a total transaction of C$48,450.00. Following the completion of the sale, the director now owns 58,000 shares in the company, valued at C$562,020.
Shares of APS opened at C$8.53 on Wednesday. The company has a 50-day simple moving average of C$9.87 and a 200-day simple moving average of C$9.10. The firm has a market capitalization of $698.67 million and a P/E ratio of -15.65. The company has a debt-to-equity ratio of 1.63, a quick ratio of 20.33 and a current ratio of 20.56. Aptose Biosciences Inc. has a 52 week low of C$2.37 and a 52 week high of C$12.62.
Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported C($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of C($0.14) by C($0.06). As a group, equities analysts forecast that Aptose Biosciences Inc. will post -0.65 earnings per share for the current year.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More: Price to Earnings Ratio (PE)
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.